Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics (MRSN)
:MRSN
MRSN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $3.96
Previous CloseN/A
Volume429.52K
Average Volume (3M)3.26M
Market Cap
$38.05M
Enterprise Value$108.28M
Total Cash (Recent Filing)-$11.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.69
Next Earnings
May 12, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding124,631,340
10 Day Avg. Volume3,516,939
30 Day Avg. Volume3,262,900
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.31
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap2.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$4.50Price Target Upside1451.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Mersana Therapeutics News
PremiumCompany Announcements
Mersana Therapeutics Reports Progress and Financial Results
PremiumCompany Announcements
Mersana Therapeutics Announces Positive Phase 1 Clinical Data---
Bulls Say, Bears Say
Bulls Say
Competitive PositioningPfizer's discontinuation of their B7-H4-targeted ADC positions Emi-Le as the leading competing asset.
Financial PerformanceMRSN reported EPS of $(0.11) vs. consensus of $(0.19) indicating better-than-expected financial performance.
Research And DevelopmentThe company has initiated dose expansion in TNBC patients, advancing their research and potential treatment options.
Bears Say
Patient Pool LimitationPatients with 5 or more prior lines of therapy will be excluded from expansion, which may limit the patient pool.
Side Effects ManagementManagement is more concerned with decreasing dose delays rather than decreasing proteinuria events, indicating ongoing challenges with managing side effects.
Uncertainty In Competitive LandscapeThe reasons behind PFE’s decision to discontinue its B7-H4 program remain unclear, leading to caution about drawing conclusions regarding its implications for MRSN.
---
Ownership Overview
17.55% Insiders
8.94% Mutual Funds
50.78% Other Institutional Investors
12.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRSN FAQ
What was Mersana Therapeutics’s price range in the past 12 months?
Mersana Therapeutics lowest stock price was $0.27 and its highest was $3.96 in the past 12 months.
What is Mersana Therapeutics’s market cap?
Mersana Therapeutics’s market cap is $38.05M.
When is Mersana Therapeutics’s upcoming earnings report date?
Mersana Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 32 days.
How were Mersana Therapeutics’s earnings last quarter?
Mersana Therapeutics released its earnings results on Mar 03, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.16 by $0.05.
Is Mersana Therapeutics overvalued?
According to Wall Street analysts Mersana Therapeutics’s price is currently Undervalued.
Does Mersana Therapeutics pay dividends?
Mersana Therapeutics does not currently pay dividends.
What is Mersana Therapeutics’s EPS estimate?
Mersana Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Mersana Therapeutics have?
Mersana Therapeutics has 124,631,340 shares outstanding.
What happened to Mersana Therapeutics’s price movement after its last earnings report?
Mersana Therapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.16. Following the earnings report the stock price went down -7.692%.
Which hedge fund is a major shareholder of Mersana Therapeutics?
Currently, no hedge funds are holding shares in MRSN
---
Mersana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (1451.72% Upside)
$4.50 (1451.72% Upside)
Hedge Fund Trend
Increased
By 9.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.98%
12-Months-Change
Fundamentals
Return on Equity
-505.14%
Trailing 12-Months
Asset Growth
-36.01%
Trailing 12-Months
Company Description
Mersana Therapeutics
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
---
MRSN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Mersana, highlighted by promising clinical data and a strong safety profile for Emi-Le, as well as increased collaboration revenues and reduced net loss. However, dose management challenges and market competition remain areas of concern.Read More>---
MRSN Stock 12 Month Forecast
Average Price Target
$4.50
▲(1451.72% Upside)
Technical Analysis
Sarepta Therapeutics
―
MacroGenics
―
Karyopharm Therapeutics
―
TG Therapeutics
―
Blueprint Medicines
―
Best Analysts Covering MRSN
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-9.39%
reiterated a buy rating last month
Copying David Nierengarten's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -9.39% per trade.
---